Estrella Immunopharma (ESLA) Income Statement: Revenue & Earnings

Estrella Immunopharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Estrella Immunopharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Jun 2023	Jun 2022	Jun 2021
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	6.41	10.45	1.39	0.46
Selling, General & Administrative	2.44	0.66	0.30	0.28
Operating Expenses	8.85	11.11	1.69	0.73
Operating Income	-8.85	-11.11	-1.69	-0.73
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00
Other Income/Expense	0.00	0.00	0.00	0.00
Income
Income Before Tax	-8.85	-11.11	-1.69	-0.73
Income Tax Expense	0.00	0.00	0.00	0.00
Net Income	-8.85	-11.11	-1.69	-0.73
Net Income - Continuous Operations	-8.85	-11.11	-1.69	-0.73
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	-8.85	-11.11	-1.69	-0.73
EBIT	-7.31	-11.11	-1.69	-0.73
Depreciation & Amortization	-0.04	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-	-36.00	-	-
Diluted EPS	-	-36.00	-	-
Basic Shares Outstanding	36.68	0.31	35.20	35.20
Diluted Shares Outstanding	36.68	0.31	35.20	35.20